Related Experiment Video

Updated: Aug 20, 2025

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of

Jichang Luo1,2, Wanying Liao3, Xue Wang4

  • 1China International Neuroscience Institute (China-INI), Beijing, China.

BMJ Open
|November 24, 2022
PubMed

Insights

This systematic review will analyze the anti-inflammatory effects of Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in atherosclerosis. The goal is to clarify their role in managing cardiovascular disease by examining inflammatory markers.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Pharmacology

Background:

  • Atherosclerosis, a major cause of cardiovascular disease (CVD) mortality, involves lipid accumulation and inflammation.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel lipid-lowering agents with potential anti-inflammatory properties.
  • The precise anti-inflammatory impact of PCSK9 inhibitors in atherosclerosis remains unclear.

Purpose of the Study:

  • To systematically review and meta-analyze the anti-inflammatory effects of PCSK9 inhibitors in patients with atherosclerosis.
  • To assess the impact of PCSK9 inhibitors on both circulating and local inflammatory markers.
  • To provide evidence-based insights into the role of PCSK9 inhibitors in CVD prevention.

Main Methods:

  • A systematic review and meta-analysis following PRISMA guidelines.
  • Inclusion of double-blind, randomized controlled trials (RCTs) with a minimum 2-week treatment duration.
  • Searches of major databases (PubMed, Embase, Web of Science, Cochrane) from 2003 onwards for relevant studies.

Main Results:

  • The review will quantify changes in inflammatory markers such as C-reactive protein, IL-6, and TNF-α.
  • Local inflammatory markers, including target-to-background ratios, will also be analyzed.
  • Quality of evidence, heterogeneity, and reporting bias will be assessed.

Conclusions:

  • This study aims to elucidate the anti-inflammatory efficacy of PCSK9 inhibitors in atherosclerosis.
  • Findings will contribute to understanding the therapeutic potential of PCSK9 inhibitors beyond lipid lowering.
  • Results will inform clinical practice regarding the use of PCSK9 inhibitors for CVD prevention.
Abstract

Keywords:
CLINICAL PHARMACOLOGYCoronary heart diseaseLipid disordersProtocols & guidelinesVASCULAR MEDICINE

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.2K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
751
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
35